Zobrazeno 1 - 10
of 222
pro vyhledávání: '"hr+"'
Publikováno v:
Cancer Management and Research, Vol Volume 16, Pp 491-505 (2024)
Jie-Yu Zhou,1 Cheng-Geng Pan,1 Yang Ye,1 Zhi-Wei Li,1 Wei-Da Fu,2 Bin-Hao Jiang3 1Department of Thyroid and Breast Surgery, The Wenzhou Central Hospital, Wenzhou, Zhejiang, 325000, People’s Republic of China; 2Department of Thyroid and Breast Surge
Externí odkaz:
https://doaj.org/article/ac69318d2764446f8203fd0cfe208fc7
Autor:
Ruth Moulson, Guillaume Feugère, Tracy S. Moreira-Lucas, Florence Dequen, Jessica Weiss, Janet Smith, Christine Brezden-Masley
Publikováno v:
Current Oncology, Vol 31, Iss 4, Pp 2172-2184 (2024)
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are widely used in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 negative (HER2−) advanced/metastatic breast cancer (ABC/MBC) in first line (1L), but little i
Externí odkaz:
https://doaj.org/article/16198dbde7934a8f8964bc4ddb4c567e
Autor:
Arif Ali Awan, Deanna Saunders, Gregory Pond, Caroline Hamm, Nadia Califaretti, Mihaela Mates, Vikaash Kumar, Mohammed F. K. Ibrahim, Ana-Alicia Beltran-Bless, Lisa Vandermeer, John Hilton, Mark Clemons
Publikováno v:
Current Oncology, Vol 31, Iss 3, Pp 1278-1290 (2024)
For early-stage hormone receptor (HR)-positive and HER2-negative breast cancer, tools to estimate treatment benefit include free and publicly available algorithms (e.g., PREDICT 2.1) and expensive molecular assays (e.g., Oncotype DX). There remains a
Externí odkaz:
https://doaj.org/article/59ac03d441804b9a97079eb978d6a8a8
Publikováno v:
Sensors, Vol 24, Iss 17, p 5713 (2024)
Low-cost, portable devices capable of accurate physiological measurements are attractive tools for coaches, athletes, and practitioners. The purpose of this study was primarily to establish the validity and reliability of Movesense HR+ ECG measuremen
Externí odkaz:
https://doaj.org/article/1a16908efcbb4a52871a1559ace43320
Autor:
Elias Obeid, Rohan C. Parikh, Elizabeth Esterberg, Bhakti Arondekar, Abigail Hitchens, Lillian Shahied Arruda, Alexander Niyazov, Kristen Whitaker
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
AimTo examine clinical characteristics, real-world treatment patterns, and health outcomes among patients with germline BRCA1/2-mutated, human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer (ABC).MethodsA retrospective an
Externí odkaz:
https://doaj.org/article/87cee8aa415a4c878d1bef57e7b50c16
Publikováno v:
Health Economics Review, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Background Palbociclib and Ribociclib are cyclin-dependent kinase 4/6 oral molecular inhibitors that have the potential to improve overall survival (OS), progression-free survival (PFS), and quality of life in patients with metastatic breast
Externí odkaz:
https://doaj.org/article/78e13d619bcc46f4acade553bcbd3f11
Autor:
Nar Bahadur Katuwal, Min Sil Kang, Mithun Ghosh, Sa Deok Hong, Yeong Gyu Jeong, Seong Min Park, Seul-Gi Kim, Joohyuk Sohn, Tae Hoen Kim, Yong Wha Moon
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-21 (2023)
Abstract Background Breast cancer is the global leading cancer burden in women and the hormone receptor-positive (HR+) subtype is a major part of breast cancer. Though cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are highly effective therapy f
Externí odkaz:
https://doaj.org/article/d6b66fd44da1438f93bf7bcc8096c727
Autor:
Christine Song, Dawa Jung, Ayse Tuba Kendi, Jin Kyung Rho, Eun-Joo Kim, Ian Horn, Geoffry L. Curran, Sujala Ghattamaneni, Ji Yeon Shim, Pil Soo Kang, Daehun Kang, Jay B. Thakkar, Sannidhi Dewan, Val J. Lowe, Seung Baek Lee
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 13, p 7494 (2024)
Women with type 2 diabetes (T2D) have a higher risk of being diagnosed with breast cancer and have worse survival than non-diabetic women if they do develop breast cancer. However, more research is needed to elucidate the biological underpinnings of
Externí odkaz:
https://doaj.org/article/e9136e9e4e914459aa0afd7ac8cfc69c
Autor:
Veruschka Albert, Christina Bruss, Deniz Tümen, Gerhard Piendl, Florian Weber, Edgar Dahl, Stephan Seitz, Olaf Ortmann, Anja K. Wege, Gero Brockhoff
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 13, p 7475 (2024)
The impact of the HER4 receptor on the growth and treatment of estrogen receptor-positive breast cancer is widely uncertain. Using CRISPR/Cas9 technology, we generated stable HER4 knockout variants derived from the HER4-positive MCF-7, T-47D, and ZR-
Externí odkaz:
https://doaj.org/article/61e2188f6cf64a2d937a9fff9c763493
Autor:
Dongqing Pu, Yue Wu, Debo Xu, Guangxi Shi, Hanhan Chen, Dandan Feng, Mengdi Zhang, Jingwei Li
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background: The clinical selection of three CDK4/6 inhibitors presents a challenging issue, owing to the absence of distinct clinical case characteristics, biomarkers, and their comparable clinical benefits in progression-free survival and overall su
Externí odkaz:
https://doaj.org/article/d31f50dddbc84c8c819c0cf614dffec1